Khera Nandita, Emmert Amy, Storer Barry E, Sandmaier Brenda M, Alyea Edwin P, Lee Stephanie J
Division of Hematology/Oncology, Mayo Clinic in Arizona, Phoenix, Arizona, USA; Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Division of Hematology/Oncology, Mayo Clinic in Arizona, Phoenix, Arizona, USA; Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Oncologist. 2014 Jun;19(6):639-44. doi: 10.1634/theoncologist.2013-0406. Epub 2014 May 5.
Reduced intensity conditioning (RIC) regimens have allowed older patients and those with comorbidities to receive hematopoietic cell transplantation (HCT). We analyzed medical costs from the beginning of conditioning to 100 days after HCT for 484 patients and up to 2 years for 311 patients who underwent a RIC HCT at two institutions from January 2008 to December 2010. Multiple linear regression was used to analyze the association between clinical variables, center effect, and costs. Patient and transplant characteristics were comparable between the sites, although differences were seen in pretransplant performance scores. Significant predictors for lower costs for the first 100 days included a diagnosis of lymphoma/myeloma and use of human leukocyte antigen-matched related donors. Grade II-IV acute graft-versus-host disease (GVHD) was associated with higher costs. The overall short-term costs between the two institutions were comparable when adjusted for clinical variables (p = .43). Late costs between 100 days and 2 years after HCT were available for one cohort (n = 311); median costs during this period were $39,000 and accounted for 39% of costs during the first 2 years. Late costs were not associated with any pretransplant variables, but were higher with extensive chronic GVHD and death. After adjustment for clinical characteristics, the overall costs of the RIC transplants were similar between the two institutions despite different management approaches (inpatient vs. outpatient conditioning) and accounting methodologies. Use of unrelated/alternative donors, transplant for diseases other than lymphoma or myeloma, and acute GVHD were predictors for higher early costs, and extensive chronic GVHD and death were associated with higher late costs.
减低强度预处理(RIC)方案使老年患者和合并症患者能够接受造血细胞移植(HCT)。我们分析了2008年1月至2010年12月在两家机构接受RIC-HCT的484例患者从预处理开始至HCT后100天以及311例患者长达2年的医疗费用。采用多元线性回归分析临床变量、中心效应和费用之间的关联。尽管在移植前性能评分方面存在差异,但各研究点的患者和移植特征具有可比性。前100天费用较低的显著预测因素包括淋巴瘤/骨髓瘤诊断以及使用人类白细胞抗原匹配的相关供者。II-IV级急性移植物抗宿主病(GVHD)与较高费用相关。在对临床变量进行调整后,两家机构的总体短期费用具有可比性(p = 0.43)。一个队列(n = 311)提供了HCT后100天至2年的后期费用;在此期间的中位费用为39,000美元,占前2年费用的39%。后期费用与任何移植前变量均无关联,但在广泛慢性GVHD和死亡情况下费用较高。在对临床特征进行调整后,尽管管理方法(住院与门诊预处理)和计费方法不同,但两家机构RIC移植的总体费用相似。使用无关/替代供者、移植淋巴瘤或骨髓瘤以外的疾病以及急性GVHD是早期费用较高的预测因素,而广泛慢性GVHD和死亡与后期费用较高相关。